期刊文献+

COPD稳定期合并肺动脉高压患者的Intermedin、尾加压素Ⅱ水平观察 被引量:4

下载PDF
导出
摘要 目的探讨血浆Intermedin(IMD)、尾加压素Ⅱ(UⅡ)水平与慢性阻塞性肺疾病(COPD)并发肺动脉高压(PH)的相关性。方法应用超声心动图测定65例老年COPD稳定期患者的肺动脉压(PAP),根据是否存在PH将患者分为PH组30例和无PH组35例;另择健康查体者30例作为对照组。比较三组血浆IMD、UⅡ含量,分析血浆IMD、UⅡ含量与PAP和动脉血氧分压(PaO2)的相关性。结果 PH组和无PH组的血浆IMD含量较对照组均明显降低(P均<0.05),血浆UⅡ含量较对照组均明显升高(P均<0.05);PH组IMD含量明显低于无PH组(P<0.05),血浆UⅡ含量明显高于无PH组(P<0.05);PH组PAP与血浆IMD含量呈显著负相关(r=-0.83,P<0.05),与血浆UⅡ含量呈显著正相关(r=0.72,P<0.05)。结论 IMD、UⅡ在PH形成和血管收缩及舒张中起重要作用,其失衡及血管重塑可能是COPD发展为PH的基础,血浆IMD及UⅡ含量可作为判断PH严重程度的指标之一。
出处 《山东医药》 CAS 2012年第37期61-62,共2页 Shandong Medical Journal
  • 相关文献

参考文献7

  • 1Gou C, Ding J, Yao L, et al. Tumor suppressor gene Runx3 sensiti- zes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1[J]. Int J Cancer, 2005,116 ( 1 ) : 155- 160.
  • 2蔡柏蔷.慢性阻塞性肺疾病合并肺动脉高压诊治的新认识[J].中国实用内科杂志,2010,30(12):1068-1071. 被引量:26
  • 3Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD[J]. Chest, 2008,134(4) :808-814.
  • 4Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD[ J]. Chest, 2011,139( 1 ) :165-173.
  • 5Roh J, Chang CL, Bhalla A, et al. Intermedin is a calcitonin/calci- tonin gene-related peptide family peptide acting through the calcito- nin receptor-like receptor/receptor activity-modifying protein recep- tor complexes[J]. J Biol Chem, 2004,79(8) :7264-7274.
  • 6Burak Kandilci H, Gumusel B, Wasserman A, et al. Intermedin/ adrenomeduHin-2 dilates the rat pulmonary vascular bed: Depend- ence on CGRP receptors and nitric oxide release [ J ]. Peptides, 2006,27(6) :1390-1396.
  • 7MaeLean MIL, Alexander D, Stirrat A, et al. Contractile responses to human urotensin- II in rat and human pulmonary arteries : effect of endothelial factors and chronic hypoxia in the rat[J]. Br J Pharma- col, 2000,130(2) :201-204.

二级参考文献8

  • 1Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD[ J]. Eur Respir J,2008,32 : 1371 - 1385.
  • 2Peinado VI, Pizarro S, Barberu JA. Pulmonary vascular involvement in COPD[ J]. Chest,2008,134:808 - 814.
  • 3Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD : epidemiology, significance, and management [ J ]. Chest, 2010,137 (6) :39S-51S.
  • 4Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity [ J ]. Eur Respir J ,2008,31:759 - 764.
  • 5Barnes PJ. Fulure treatments for chronic obstructive pulmonary, dis- ease and its comorbidities [ J ]. Proc Am Thorac Soc, 2008,5 : 857 - 864.
  • 6Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and fonner smokers [ J ]. Chest ,2007,132 : 1764 - 1771.
  • 7Hoeper MM. Treating pulmonary hypertension in COPD:where do we start? [J]. Eur Respir J,2008,32:541 -542.
  • 8Galie N, Hoeper MM, Humbert M,et al. Guidelines for the diagno- sis and treatment of pulmonary hypertension [ J ]. Eur Respir J, 2009,34 : 1219 - 1263.

共引文献25

同被引文献18

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部